This digital approach is part of the health system’s overall “omics” strategy that will also focus on rare diseases, genetic testing and new technologies to study cell functioning, relying on artificial intelligence to analyze massive datasets.
“We are living in a transformative time where big data and AI will create tremendous opportunities for improving how we prevent and care for disease,” said Konstantinos Lazaridis, MD, the Carlson and Nelson Endowed Executive Director for Mayo Clinic’s Center for Individualized Medicine, in a May 9 statement.
Digital omics will entail making all this data available to clinicians in EHRs, including the health system’s huge Tapestry genomics study, through data governance and standardized definitions. Mayo Clinic is also developing AI algorithms to identify primary care patients who might benefit from genetic testing.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
